JPWO2020148526A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020148526A5 JPWO2020148526A5 JP2021563433A JP2021563433A JPWO2020148526A5 JP WO2020148526 A5 JPWO2020148526 A5 JP WO2020148526A5 JP 2021563433 A JP2021563433 A JP 2021563433A JP 2021563433 A JP2021563433 A JP 2021563433A JP WO2020148526 A5 JPWO2020148526 A5 JP WO2020148526A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- referred
- sar
- peptide ligand
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- 239000003446 ligand Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 108700012439 CA9 Proteins 0.000 description 4
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 239000002062 molecular scaffold Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GHITVUOBZBZMND-UHFFFAOYSA-N 1,3,5-tris(bromomethyl)benzene Chemical compound BrCC1=CC(CBr)=CC(CBr)=C1 GHITVUOBZBZMND-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1900526.3 | 2019-01-15 | ||
| GBGB1900526.3A GB201900526D0 (en) | 2019-01-15 | 2019-01-15 | Bicyclic peptide ligands specific for caix |
| PCT/GB2020/050070 WO2020148526A1 (en) | 2019-01-15 | 2020-01-15 | Bicyclic peptide ligands specific for caix |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517442A JP2022517442A (ja) | 2022-03-08 |
| JPWO2020148526A5 true JPWO2020148526A5 (https=) | 2023-01-25 |
| JP2022517442A5 JP2022517442A5 (https=) | 2023-01-25 |
Family
ID=65528170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563433A Pending JP2022517442A (ja) | 2019-01-15 | 2020-01-15 | Ｃａｉｘに特異的な二環式ペプチドリガンド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220133732A1 (https=) |
| EP (1) | EP3911743A1 (https=) |
| JP (1) | JP2022517442A (https=) |
| CN (1) | CN113383074A (https=) |
| GB (1) | GB201900526D0 (https=) |
| WO (1) | WO2020148526A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6882978B2 (ja) | 2014-10-29 | 2021-06-02 | バイスクルアールディー・リミテッド | Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド |
| JP7301757B2 (ja) | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
| CN111183147B (zh) | 2017-08-04 | 2024-07-05 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| JP2021514953A (ja) | 2018-02-23 | 2021-06-17 | バイスクルテクス・リミテッド | 多量体二環式ペプチドリガンド |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| US12551567B2 (en) | 2018-12-21 | 2026-02-17 | Bicyclerd Limited | Bicyclic peptide ligands specific for PD-L1 |
| JP2022514618A (ja) | 2018-12-21 | 2022-02-14 | バイスクルテクス・リミテッド | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| IL300248A (en) | 2020-08-03 | 2023-03-01 | Bicycletx Ltd | peptide-based linkers |
| US20250339569A1 (en) | 2021-12-17 | 2025-11-06 | 3B Pharmaceuticals Gmbh | Carbonic anhydrase ix ligands |
| CN118852348A (zh) * | 2022-02-11 | 2024-10-29 | C-比奥麦克斯有限公司 | 靶向碳酸酐酶ix的肽配体、包含其的肽结构体及它们的用途 |
| CN117599013A (zh) * | 2022-08-22 | 2024-02-27 | 赣州和美药业股份有限公司 | 纳米组合物及其制备方法和用途 |
| CN120230182B (zh) * | 2025-05-29 | 2025-08-22 | 北京肿瘤医院(北京大学肿瘤医院) | 经修饰的caix靶向环肽及其核素标记物与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| DK1844337T3 (da) | 2005-01-24 | 2013-09-30 | Pepscan Systems Bv | Bindingsforbindelser, immunogene forbindelser og peptidmimetika |
| AU2009211253B2 (en) | 2008-02-05 | 2014-11-06 | Bicyclerd Limited | Methods and compositions |
| JP6882978B2 (ja) | 2014-10-29 | 2021-06-02 | バイスクルアールディー・リミテッド | Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド |
| GB201607827D0 (en) * | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| WO2018197893A1 (en) * | 2017-04-27 | 2018-11-01 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| JP7301757B2 (ja) * | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
-
2019
- 2019-01-15 GB GBGB1900526.3A patent/GB201900526D0/en not_active Ceased
-
2020
- 2020-01-15 CN CN202080009486.9A patent/CN113383074A/zh active Pending
- 2020-01-15 WO PCT/GB2020/050070 patent/WO2020148526A1/en not_active Ceased
- 2020-01-15 EP EP20701119.8A patent/EP3911743A1/en not_active Withdrawn
- 2020-01-15 US US17/422,933 patent/US20220133732A1/en not_active Abandoned
- 2020-01-15 JP JP2021563433A patent/JP2022517442A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020148526A5 (https=) | ||
| JPWO2020128527A5 (https=) | ||
| JPWO2020148525A5 (https=) | ||
| JPWO2020120980A5 (https=) | ||
| JPWO2020120981A5 (https=) | ||
| JPWO2020148528A5 (https=) | ||
| AU2017336250B2 (en) | Incremental dose finding in controlled-release PTH compounds | |
| JPWO2021019243A5 (https=) | ||
| IL281277B2 (en) | Preparations and methods for treating viral infections | |
| JPWO2021019244A5 (https=) | ||
| JP2023029957A (ja) | 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生 | |
| JP2008525491A5 (https=) | ||
| JPWO2020120983A5 (https=) | ||
| JPWO2020148529A5 (https=) | ||
| KR20190062496A (ko) | 조절 방출 pth 화합물을 위한 투여 용법 | |
| JPH03118333A (ja) | フイブリノーゲンレセプター拮抗剤 | |
| JPWO2020148530A5 (https=) | ||
| JP2011518179A5 (https=) | ||
| JP2010209088A (ja) | Ｐ−セレクチンに対する結合性化合物 | |
| KR20220128390A (ko) | 부갑상선기능저하증 치료 | |
| TW201811817A (zh) | 血小板反應素１結合肽 | |
| JPWO2020148527A5 (https=) | ||
| Redman et al. | Pharmacokinetic and chemical synthesis optimization of a potent D-peptide HIV entry inhibitor suitable for extended-release delivery | |
| JPWO2021074622A5 (https=) | ||
| JPWO2023068226A5 (https=) |